{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000012","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.881395+00:00","generated_at":"2026-05-28T08:51:03.171509+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"Immuneering reports 43% ORR in first-line pancreatic combo; plans new trials in 2025","bullets":["IMM-1-104 + mGnP in 1L pancreatic: 1 complete response, 2 partial response (43% ORR), 86% DCR among 7 evaluable patients.","IMM-1-104 + mFFX in 1L pancreatic: all 4 patients had tumor shrinkage; 1 partial response with 100% target lesion reduction.","IMM-1-104 monotherapy in 2L pancreatic: 11 of 21 evaluable patients achieved disease control; 1 partial response with 67% reduction.","IMM-6-415 Phase 1 PK/PD: up to 77% pERK inhibition; generally well tolerated with no dose-limiting toxicities.","Additional Phase 2a data expected Q2 2025; plans to launch arms in melanoma and NSCLC with combinations."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000012","json":"https://secwatch.observer/filing/0001790340-25-000012.json","markdown":"https://secwatch.observer/filing/0001790340-25-000012.md","text":"https://secwatch.observer/filing/0001790340-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000012/0001790340-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000012/imrx-20250107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:51:03.171509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}